Treatment of pulmonary hypertension based on inhibition of pulmonary vascular cell proliferation
10.16438/j.0513-4870.2021-1126
- VernacularTitle:基于肺血管细胞增殖抑制的肺动脉高压治疗药物
- Author:
Xiao-nan ZHANG
1
,
2
,
3
,
4
;
Zhan-qiang LI
1
,
2
,
3
;
Dian-xiang LU
1
,
2
,
3
Author Information
1. Research Center for High Altitude Medicine, Qinghai University, Xining 810001, China
2. Key Laboratory of High Altitude Medicine, Ministry of Education
3. Key Laboratory of Application and Foundation for High Altitude Medicine Research in Qinghai Province (Qinghai-Utah Joint Research Key Lab for High Altitude Medicine), Xining 810001, China
4. Qinghai Provincial People's Hospital, Xining 810007, China
- Publication Type:Research Article
- Keywords:
pulmonary hypertension;
pulmonary arterial smooth muscle cell;
pulmonary vascular remodeling;
cell cycle;
proliferative signaling pathway
- From:
Acta Pharmaceutica Sinica
2022;57(3):557-567
- CountryChina
- Language:Chinese
-
Abstract:
Pulmonary hypertension is a rapidly progressing disease of the lung vasculature with poor prognosis, ultimately leading to right heart failure and death. The remodeling of small pulmonary arteries represents an important pathological characteristic of pulmonary hypertension. Pulmonary arterial smooth muscle cells (PASMCs) located in the middle layer of pulmonary artery exhibit hyperproliferation and resistance to apoptosis, which is the main initiator of pulmonary vascular remodeling and similar to that seen in tumor cells. In this review we focus on the signaling pathways that play a key role in PASMCs proliferation and the latest research progress on inhibitors targeting cell proliferation pathways to provide a new perspective for the treatment of PH．
